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Abbreviations (non standard) 
AZX (1-[(2R)-2-[[4-[3-chloro-4-(2-pyridyloxy)anilino]quinazolin-5-yl]oxymethyl]-1-piperi-
dyl]-2-hydroxy) 
HLM human liver microsomes 
NADPH Nicotinamide adenine dinucleotide phosphate 
GSH glutathione 
nm nanometer 
HCD higher energy collisional dissociation 
CID collision induced dissociation 
UHPLC ultra high performance liquid chromatography 
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Abstract  
The incubation of compound AZX (1-[(2R)-2-[[4-[3-chloro-4-(2-pyridyloxy)anilino] 
quinazolin-5-yl]oxymethyl]-1-piperi-dyl]-2-hydroxy) with human liver microsomes 
generated several metabolites that highlighted the hydroxyacetamide side chain was a major 
site of metabolism for the molecule.  The metabolites were derived predominantly from 
oxidative biotransformations, however two unexpected products were detected by LC-UV-
MS and identified as methanol adducts.  It became apparent that a metabolite formed in the 
microsomal incubation reacted with methanol in the mobile phase when no methanol adducts 
were detected in the analysis where acetonitrile was used.  This observation prompted further 
investigations into the metabolic modification of the parent.  Although this reactive 
metabolite could not be isolated or structurally characterised by LC-MS, several metabolic 
indications enabled the proposal of a reactive aldehyde.  Experiments using methoxyamine 
post-incubation showed the disappearance of the two methanol adducts and appearance of a 
methoxyamine adduct, confirming the presence of an aldehyde group. The proposed structure 
of the reactive aldehyde derived from oxidation of the terminal hydroxyl group on the 
hydroxyacetamide side chain, leading to the formation of the diastereoisomeric methanol 
adducts detectable by LC-UV-MS.   
 
Keywords: 6 keywords 
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Introduction 
 
Metabolite identification studies within drug discovery are generally used to identify 
metabolically labile sites on chemical structures, human metabolites which may not be 
represented in the toxicological species, active metabolites or potential reactive/toxic 
metabolites, which are of concern for the pharmaceutical industry 1 2 3.  These discovery 
studies are conducted in vitro and generally involve incubation of a test compound in 
hepatocytes or microsomes, which mimic the most prevalent metabolic processes occurring 
in the liver.  Typically, samples are taken from the test compound incubates, then added to 
acetonitrile to quench the reaction at t=0 min (control) and at a terminal time point (usually 
30–60 min). Subsequently, samples are analysed on high resolution accurate mass UHPLC-
MS/MS systems and comparison of the t=0 min vs the t=60 min samples enables easier 
identification of metabolites from endogenous components. The analysis can be both 
challenging and time consuming even when identifying only a small number of metabolites.  
Often the data has to be generated and reported quickly to impact the chemistry design and 
unusual unexpected metabolites/products are not fully investigated due to time constraints. 
Such products can occasionally be formed through reactive or toxic metabolites.   
Here we present an unusual finding from an in vitro metabolite identification study of 
compound AZX, a representative compound from a structurally related chemical series, in 
human liver microsomes (HLM).  AZX (Figure 1) generated several metabolites in HLM that 
were predominantly oxidative biotransformation products, which highlighted the 
hydroxyacetamide side chain as a major site of metabolism for the molecule. Additionally, 
two unexpected methanol adduct products were detected with different retention times yet 
identical mass. Methanol adducts are fairly common in mass spectrometry and are normally 
identified as analytical artefacts of the parent drug, generated during the positive ion 
electrospray ionisation process. Pozo et al. (2007)4 reported the analysis of steroids using 
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electrospray generated adducts such as [M + MeOH] or [M+ Na +MeOH].  However, in this 
case AZX reacted with methanol in the mobile phase prior to the mass spectrometry 
ionisation process.  The methanol adducts not only eluted at a different retention time to the 
parent drug, but two chromatographically separate methanol adduct peaks were observed, 
indicating the presence of isomers.  These adducts were not detected in either the t=0 control 
samples or when acquired with acetonitrile as the mobile phase. This inferred a metabolic 
transformation to a reactive metabolite formed in the t=60 sample, which subsequently 
generated the methanol adducts on injection onto the UHPLC column.  The formation of 
these methanol adducts is subject to further investigation in this paper.  
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Materials and Methods 
Chemicals 
AZX 1-[(2R)-2-[[4-[3-chloro-4-(2-pyridyloxy)anilino]quinazolin-5-yl]oxymethyl]-1-piperi-
dyl]-2-hydroxy was synthesized at AstraZeneca R&D, Alderley Park, Macclesfield, UK. 
Methanol, acetonitrile, formic acid were all of analytical grade and supplied by Fisher 
Scientific (Loughborough, UK). Methoxyamine hydrochloride was sourced from Sigma-
Aldrich (Poole, UK).  All other chemicals or solvents were purchased from commercial 
suppliers and were of analytical grade. No specific safety considerations apply to any of these 
agents, although the agents should be handled with care in a fumehood to avoid inhalation or 
ingestion. 
 
AZX stock solution  
Solid AZX was dissolved in dimethyl sulfoxide to a concentration of 10 mM  
 
In vitro incubation spiking solution   
AZX dimethyl sulfoxide stock was diluted with 0.1 M potassium phosphate buffer (pH 7.4) 
to a concentration of 2 mM. This solution was then spiked into the in vitro incubation at 
1:100 (v/v) to give a final concentration in the incubation of 20 uM. 
 
In vitro incubation experimental methods  
Three separate incubations were performed with parent compound (AZX):  
 
 
A) AZX was incubated at 20 μM with HLM (2 mg protein/mL, BD-Gentest 150 donor 
ultrapool) in 0.1 M potassium phosphate buffer at pH 7.4 and 2.5 mM Nicotinamide adenine 
dinucleotide phosphate (NADPH) at 37 °C. An aliquot was removed after 0 min (control) and 
60 min and the reaction stopped by the addition of ice cold MeCN (1:1, v/v). 
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B) AZX was incubated as described in A, but with 10 mM methoxyamine trapping agent 
added. An aliquot was removed after 60 minutes and the reaction stopped by the addition of 
ice cold MeCN (1:1, v/v). 
 
C) AZX was incubated as described in A. An aliquot was removed after 60 min and the 
reaction stopped by the addition of ice cold MeCN (1:1, v/v) containing 10 mM 
methoxyamine. The extract was then incubated for a further 10 min at 37°C. 
 
D) AZX was incubated as described in A, but with 10 mM GSH trapping agent added. An 
aliquot was removed after 60 minutes and the reaction stopped by the addition of ice cold 
MeCN (1:1, v/v).  
 
 
Sample preparation – analytical incubation 
Quenched incubates were centrifuged at ca. 3000g for 15 min, and the supernatant retained. 
An aliquot of the the supernatant was transferred to a Waters HPLC 2 mL vial and diluted 1:3 
(v/v) with ultra purified distilled water prior to the LC-MS analyses. 
 
Profiling and Structural characterisation of metabolites by UPLC-LTQ-Orbitrap Mass 
spectrometry 
Accurate mass structural characterisation work was acquired on a LTQ Orbitrap XL (Thermo 
Fisher Scientific, Bremen, Germany) connected to a Waters Acquity UPLCTM system. The 
Waters Acquity system (Waters, Milford, MA, USA) consisted of a binary UPLC Pump, 
column oven, a sample manager and a photodiode array detector.  Separation was carried out 
on a Waters BEH C18 (100 x 2.1 mm, 1.7 µM) (Waters, Milford, MA, USA), preceded by a 
guard filter in a column oven at 50 ºC.   
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Two chromatographic methods were used. Method 1: The mobile phase consisted of formic 
acid (0.1% in water, eluent A) and methanolic formic acid (0.1%, eluent B).  Method  2: The 
mobile phase consisted of formic acid (0.1% in water, eluent A) and acetonitrile containing 
formic acid (0.1%, eluent B).  The elution profile for both methods was: Initial conditions 
95% A, then a linear gradient to 20% A from 1.01 min to 9.00 min, isocratic hold at 2% A 
from 9.01 to 11.00 min and re-equilibration 95% A from 11.00 min to 14.00 min.  The flow 
rate was 0.45 mL/min and the eluent was introduced into the mass spectrometer via the LTQ 
divert valve at 1 min.  The injection volume was 20 µL and UV spectra were acquired over 
200-350 nm. The LTQ-Orbitrap XL was equipped with an electrospray ionisation (ESI) 
source which was operated in positive ion mode.  Positive ion source settings were: capillary 
temperature 300 ºC, sheath gas flow 25, auxiliary gas flow 17, sweep gas flow 5, source 
voltage 3.5 kV, source current 100.0 µA, capillary voltage 18 V, tube lens 75.0 V.  Full scan 
MS data were obtained over the mass range of 100 to 1200 Da.  Full scan MS data were 
obtained over the mass range of 100 to 1200 Da. Targeted MS/MS experiments were 
acquired in the Orbitrap using Higher Energy Collisional Dissociation (HCD) fragmentation, 
isolation width 3 Da, normalised collision energy 60 eV, and activation time 30 ms. All Ion 
trap MSn experiments were acquired using collision induced dissociation (CID), isolation 
width 3 Da, normalised collision energy 35 eV and activation time 30 ms.  All ions acquired 
in the Orbitrap were monitored at 7500 resolution FWHM (full width at half maximum).  
LTQ and Orbitrap mass detectors were calibrated within one day of commencing the work 
using Proteomass LTQ/FT-Hybrid ESI positive mode calibration mix (Supelco, Bellefonte, 
USA). 
 
Data Analysis 
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Mass spectrometric data were collected using Xcalibur version 2.1 (Thermo Fisher Scientific, 
Bremen, Germany). Components were identified as being derived from AZX by common 
fragments, isotopic pattern (Chlorine), UV absorbance and accurate mass. Comparisons with 
T=0 incubations were conducted to minimise the potential for false positives from system 
impurities and endogenous components. 
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Results  
 
The initial full characterization of test compound with accurate mass MS/MS fragmentation 
often allows structural motifs and characteristic fragment ions to be identified, which assist 
the elucidation of the metabolite structures. MS/MS fragmentation experiments were 
undertaken in positive ion for the structural characterisation of metabolites or chemical 
addition products. All accurate mass measurements including the MS/MS fragmentation were 
within ±3ppm of the theoretical accurate mass.  
 
Structural characterization of AZX by LC-MS/MS 
In positive ion mode AZX yielded a protonated molecular ion at [M+H]+=520.1749 Da 
(+0.56 ppm mass error) and showed a characteristic chlorine pattern. The proposed 
dissociation pattern and LTQ Orbitrap HCD MS/MS spectrum (Figure 1) revealed 3 key 
product ions at m/z 365.0797 (corresponding to loss of the methylpiperidylethanone), m/z 
156.1018 (methylpiperidylethanone) and m/z 98.0964 (methylpiperazine). 
 
Structural characterization of the acid metabolite (+O -H2) by LC-MS/MS 
In positive ion mode the acid metabolite yielded a protonated molecular ion displaying the 
characteristic chlorine pattern with an accurate mass of [M+H]+ =534.1539Da (0.0ppm mass 
error), which is consistent with addition of one oxygen and loss of two hydrogen atoms. The 
proposed fragmentation pattern and LTQ Orbitrap HCD MS/MS spectrum (Figure 2) 
revealed diagnostic product ions; m/z 365.0789, 170.0808, 126.0911 and 98.0963. Product 
ion m/z 170.0808 corresponded to the addition of 14 Da to m/z 156.1018  observed in AZX. 
By accurate mass it was confirmed this addition was one oxygen atom and loss of two 
hydrogens to the methylpiperidylethanone group. Detection of the methylpiperazine fragment 
(m/z 98.0963, also observed in AZX) confirmed the piperazine ring was unchanged and the 
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biotransformation had occurred on the hydroxyacetamide side chain.  The product ion m/z 
126.0911 represents loss of CO2 from the hydroxyacetyl side chain, which is consistent with 
an acid on the terminal side chain carbon.  
 
Structural characterization of the hydrate product (+O) by LC-MS/MS 
The hydrate metabolite was only detected at trace levels when methanol was used as a mobile 
phase eluent, but it was the predominant species when acetonitrile.was used  Therefore the 
MS/MS spectra shown in Figure 3 for the hydrate are from the LC-MS analysis where 
acetonitrile mobile phase eluent was employed.  In positive ion mode the hydrate product 
yielded a protonated molecular ion displaying a characteristic chlorine pattern with an 
accurate mass of [M+H]+ =536.1691 Da, (+0.79ppm mass error), which is consistent with 
addition of one oxygen atom. The proposed dissociation pattern and LTQ Orbitrap HCD 
product ion MS/MS spectrum (Figure 3) revealed diagnostic product ions; m/z 172.0964, 
126.0911 and 98.0963. The m/z 172.0964 product ion corresponded to the addition of 16 Da 
to the m/z 156.1018 product ion observed in AZX and the accurate mass confirmed addition 
of one oxygen atom to the methylpiperidylethanone group. Detection of the methylpiperazine 
product ion (m/z 98.0963, also observed in AZX) confirmed the piperazine ring was 
unchanged and the oxygen atom addition had occurred on the hydroxyacetamide side chain.  
The m/z 126.0911 product ion represents loss of CH2O2 from this side chain, which is 
consistent for a hydrate on the terminal carbon.  
 
Structural characterization of the methanol addition product (a hemiacetal) by LC-
MS/MS 
Two distinct LC-UV/MS peaks were detected in the chromatogram for this product.  In 
positive ion mode the methanol addition products yielded protonated molecular ions 
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displaying characteristic chlorine patterns with an accurate mass of [M+H]+ =550.1854 Da 
(+0.41ppm mass error) and [M+H]+ =550.1852 Da (+0.12ppm), which is consistent with 
addition of one carbon, two hydrogens and an oxygen atom.  The proposed dissociation 
pattern and LTQ Orbitrap HCD product ion MS/MS spectrum for both adducts (Figure 4) 
revealed diagnostic product ions m/z 186.1121, m/z 126.0911 and m/z 98.0963. The product 
ion m/z 186.1121 corresponded to the addition of 30 Da to m/z 156.1018  observed in the 
MS/MS spectrum of AZX, and accurate mass confirmed addition of one carbon, two 
hydrogens and an oxygen to the methylpiperidylethanone group.  Detection of the 
methylpiperazine product ion  (m/z 98.0963, also observed in AZX) confirmed the piperazine 
ring was unchanged and addition of CH2O occurred on the hydroxyacetamide side chain. The 
m/z 126.0911 product ion represents loss of C2H4O2 from this side chain, confirming it as the 
site of methanol addition.  
 
The observation of two distinct LC-UV-MS peaks both with accurate masses within 2ppm of 
[M+H]+= 550.1854 (theroetical mass of AZX+CH2O) and identical MS/MS fragmentation 
(Figure 4), suggested formation of isomers. The addition of methanol to the terminal carbon 
on the hydroxyacetamide side chain creates a second chiral centre and therefore 
diastereoisomers, which could be separated chromatographically (Figure 5a).  
 
These data (the observation of the hydrate and the hemi-acetal) suggested that the potential 
reactive intermediate had undergone structural changes on the hydroxyacetyl side chain, 
producing a reactive aldehyde, whilst the formation of the acid indicated further oxidation of 
this moiety. 
 
Glutathione and methoxyamine trapping experiments 
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To confirm the reactive intermediate, the proposed reactive aldehyde, two trapping 
experiments in HLM were undertaken. The first involved using glutathione (GSH), the 
routine industry standard for trapping electrophilic reactive metabolites and methoxyamine 
which forms adducts with reactive aldehydes 5 6 7 8. The incubation of AZX with GSH did not 
produce an adduct (data not shown), instead, only the methanol adducts were detected, 
confirming that the reactive intermediate was not a soft electrophilic species.  In contrast, the 
incubation of AZX with methoxyamine generated the corresponding methoxyamine adduct, 
whilst the methanol adducts were not detected. Incubation of AZX in HLM showed almost 
complete turnover of the AZX at t=60 min (Figure 5a), however when co-incubating with 
methoxyamine the overall metabolic turnover was reduced, resulting in a significant amount 
of AZX-parent remaining unmetabolised (Figure 5b). Additionally hydroxyl metabolites of 
the methoxyamine adduct were detected at significantly greater concentration than the 
methoxyamine adduct itself (Figure 5b).  It was therefore decided to repeat the 
methoxyamine trapping experiment, this time spiking the methoxyamine post-incubation into 
the HLM immediately after quenching (at t=60 min).  This resulted in increased metabolic 
turnover of AZX and the formation of only one methoxyamine adduct with significantly 
increased yield, simplifying the data interpretation (Figure 5c).  
 
Structural characterization of the methoxyamine adduct by LC-MS/MS 
In positive ion mode the methoxyamine adduct yielded a protonated molecular ion displaying 
a characteristic chlorine pattern with an accurate mass of [M+H]+ =547.1855 Da (+0.35ppm 
mass error), which is consistent with addition of one carbon, one hydrogen and one nitrogen 
(CHN).  The addition of CHN was an expected modification upon reaction of an aldehyde 
with methoxyamine.  The proposed dissociation pattern and the LTQ Orbitrap HCD MS/MS 
spectrum (Figure 6) revealed diagnostic product ions m/z 183.1124, m/z 152.0942, m/z 
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123.0552 and m/z 96.0808. The product ion m/z 186.1121 corresponded to the addition of 27 
Da to m/z 156.1018 observed in the MS/MS spectrum of AZX and accurate mass confirmed 
addition of CHN to the methylpiperidylethanone group.  The m/z 152.0942 ion corresponded 
to the loss of a methanol radical from m/z 183.1124 ion.  
The adduct formation with methoxyamine provided evidence to the presence of an aldehydic 
functional group, and therefore confirmed the formation of a reactive aldehyde intermediate 
following oxidation of the terminal hydroxy. 
The metabolic fate of AZX, the formation of the methanol adduct and the methoxyamine 
adduct are summarised in Figure 7 and TOC. 
 
Discussion  
This study demonstrated that compound AZX on incubation with HLM generated a reactive 
aldehyde metabolite that subsequently formed two methanol adduct isomers (Figure 7). 
Whilst the reactive aldehyde metabolite was not directly detected and therefore not 
structurally verified by UHPLC-MS, the methoxyamine trapping experiment proved the 
presence of an aldehydic functional group.  MSn experiments carried out on the 
methoxyamine adduct confirmed that addition occurred on the hydroxyacetamide side chain.  
Detection of the hydrate product, gave further support for metabolism of the 
hydroxyacetamide side chain to the corresponding oxoacetamide (reactive aldehyde). The 
identification of two chromatographically distinct methanol adduct peaks with identical 
accurate masses (within ± 1ppm) and dissociation patterns is indicative of the formation of 
diastereoisomerisms. Chemical addition of methanol to the reactive aldehyde metabolite 
created an additional chiral centre and resulted in the formation of diastereoisomers, which 
were easily separated by UHPLC (Figure 5a).  Overall, the metabolic profile of AZX 
incubated in HLM showed that AZX was readily metabolised, with little evidence of AZX 
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parent in the LC-UV chromatograms (Figure 5). The aldehyde, hydrate and methanol adduct 
were likely to be in equilibrium.  In acidified methanol/water mobile phase the methanol 
adducts appeared to be the predominant species, with the hydrate detected only at trace levels 
and the reactive aldehyde not detected. However in acidified acetonitrile/water mobile phase 
only a single hydrate product was detected. Chemical reactions of methanol with aldehydes 
forming hemiacetals have been reported previously by Bateman et al. (2008)9, who observed 
methanol addition to numerous components of secondary organic aerosol when methanol was 
used for extraction and/or storage.  They also observed an increased  rate of methanol adduct 
formation in acidified solutions.  A series of publications have reported the formation of 
artefacts when methanol was used as a diluent to spike test compounds into microsomal 
incubations.  Yin et al (2001) 10 and Li et al (2006)11described the formation of +12 Da 
artefacts (having gained 1 carbon atom over incubated parent compound) from microsomal 
incubations, where methanol was present in the spiking diluent at 1% (v/v).  Similarly 
Cunningham et al (1990)12 reported the formation of an unusual -CH2 bridged dimer of 2,4-
diaminotoluene again through the presence of methanol in the diluent.  In these examples, 
methanol in the spiking solution was metabolised in the microsomal incubation to 
formaldehyde, which subsequently reacted with the test compounds containing 1,2-diamino, 
1,2 amino hydroxy or 2,4 diaminotoluene.  This is in contrast to this study, where methanol 
had not been added to the incubation or the sample extract prior to injection onto the LC-UV-
MS system, confirming the addition occurred post-injection on the LC-column, with the 
mobile phase the source of the methanol  
The initial methoxyamine HLM incubation with AZX resulted in a significant reduction of 
metabolic turnover of parent compared to the control (incubation without methoxyamine, as 
shown in Figure 5a) and the generation of additional products due to further metabolism of 
the methoxyamine adduct.  The reduction in metabolic turnover was almost certainly due to 
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enzyme inhibition by addition of methoxyamine to the incubation.  Zhang et al13 reported on 
the inhibitor properties of methoxyamine against P450 enzymes CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4/5 at concentrations up to 10mM.  To improve data quality 
and yield of the methoxyamine adduct the experiment was repeated, adding methoxyamine 
‘post-quench’ then incubating for a further 10 min at 37°C.  The result was a much cleaner 
metabolic profile; with no reduction in metabolic turnover and a significant increase in yield 
of the methoxyamine adduct (shown in Figure 5). Although the aldehyde metabolite is 
reactive, it was present at a high enough concentration immediately post-incubation to 
produce the methoxyamine adduct.  This is in agreement with the facile reaction of the 
reactive aldehyde and methanolic mobile phase on column forming the isomeric methanol 
adducts.  Aldehyde metabolites are capable of reacting with macromolecules such as proteins, 
forming covalent adducts potentially triggering direct cell toxicity or an immune response 
and have been implicated in adverse drug reactions observed in the clinic. Several drugs are 
suspected of generating reactive aldehyde metabolites implicated in adverse drug reactions, 
which include Acyclovir nephrotoxicity 14, Abacavir idiosyncratic hypersensitivity with 
increased risk of cardiac dysfunction 15 and Felbamate, aplastic anemia and hepatotoxicity 16.  
It is therefore prudent to identify compounds or structural moieties that form reactive 
aldehyde metabolites early in drug discovery to modify or change the chemistry and remove 
the liability.  It is also important to note that AZX did not form an adduct in the HLM GSH 
trapping experiment, thus escaping detection from the early routine in-house reactive 
metabolite screen.  Without the formation of the methanol adducts, the aldehyde may not 
have been identified until much later in drug discovery.   
 
In conclusion, analytical artefacts (such as methanol adducts) are not desired and can confuse 
the analysis or lead to misinterpretation. However, here we presented an example where the 
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methanol adducts were diagnostic and pivotal in identifying a reactive aldehyde metabolite, 
thus highlighting the importance of fully investigating any unusual adducts observed in 
metabolite identification studies. 
Whilst the reactive aldehyde metabolite could be proposed from the detection of methanol 
adducts, the hydrate metabolite is simply addition of Oxygen (+16 amu) to parent compound, 
which is a very common biotransformation reaction.   If the initial analysis had been 
undertaken in acetonitrile it is likely that the hydrate would have been reported as a simple 
hydroxylated metabolite and the reactive aldehyde liability for the chemical series missed. 
 
In summary, the proposed bioactivation of AZX occurred via the reactive aldehyde 
intermediate, which It is important to note that readily reacted with methanol to form a pair of 
isomeric hemiacetal methanol adducts. The reactive aldehyde metabolite was not detected 
and could not be structurally characterized directly, in acidified methanol the equilibrium 
favoured the methanol adduct and in acidified acetonitrile it favoured the hydrate.   
The aldehyde did not form an adduct with GSH, escaping detection in our conventional in 
vitro trapping screen, however, it was trapped with methoxyamine. A significant efficiency 
gain (>20 fold increase in yield of adduct) was observed when methoxyamine was added 
immediately post incubation over the traditional method, where methoxyamine is added pre 
incubation. 
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Figure 1. Accurate mass HCD MS/MS positive product ion mass spectrum of AZX (bottom) 
and proposed product ions with theoretical accurate mass and mass error in ppm (top).  
 
Figure 2. Accurate mass HCD MS/MS positive product ion mass spectrum of the acid 
metabolite (bottom) and proposed product ions with theoretical accurate mass and mass error 
in ppm (top). 
 
Figure 3. Accurate mass HCD MS/MS positive product ion mass spectrum of the hydrate 
(bottom) and proposed product ions with theoretical accurate mass and mass error in ppm 
(top). 
 
Figure 4. Accurate mass HCD MS/MS positive product ion mass spectra of the methanol 
adducts the hemiacetal (bottom) and proposed product ions with theoretical accurate mass 
and mass error in ppm (top).   
 
Figure 5. Extracted UV chromatograms (330 nm) of AZX incubated in (a) HLM (b) HLM + 
methoxyamine (c) HLM with addition of methoxyamine post-quench. 
 
Figure 6. Accurate mass HCD MS/MS positive product ion mass spectrum of the 
methoxyamine adduct (bottom) and proposed product ions with theoretical accurate mass and 
mass error in ppm (top). 
 
Figure 7. The proposed metabolic profile of AZX generated in  
HLM, together with the analytical artifact, the methanol adduct, as well as the methoxyamine 
incubation product. The proposed reactive aldehyde intermediate is shown in the centre.   
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